The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1238
July 3, 2006
View Complete Issue         Table of Contents 2019 
Insulin Detemir (Levemir), a New Long-Acting Insulin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Insulin Detemir (Levemir), a New Long-Acting Insulin
July 3, 2006 (Issue: 1238)
Insulin detemir (Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin Detemir (Levemir), a New Long-Acting Insulin
Article code: 1238b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.